Key Allergy Immunotherapy Market Players:
- ALK-Abelló
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Stallergenes Greer
- Merck KGaA
- Aimmune Therapeutics
- HAL Allergy Group
- Biomay AG
- DBV Technologies
- Allergy Therapeutics
- Leti Pharma
- WOLW Pharma
- Abbott Laboratories
- Novartis AG
- GlaxoSmithKline plc
- Johnson & Johnson
- Sanofi
- Torii Pharmaceutical Co., Ltd.
- Shionogi & Co., Ltd.
- Mitsubishi Tanabe Pharma
- ALK-Abelló Japan K.K.
- Nippon Zenyaku Kogyo
The competitive landscape of the allergy immunotherapy industry is inspiring the global players to expand their market share. Companies involved in the emerging markets of the U.S., such as Thermo Fisher Scientific and Regeneron Pharmaceuticals, are leveraging advanced injectable treatments. While other key players, including ALK-Abelló and Stallergenes Greer, are dominating the industry with sublingual and subcutaneous treatments. This is further dragging the interest in conducting research activities and bringing innovation in the field, especially for biologics and immunotherapies targeting severe allergic reactions.
Below is the list of some prominent players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of the allergy immunotherapy market was over USD 4.1 billion.
The market size for the allergy immunotherapy market is projected to reach USD 6 billion by the end of 2035, expanding at a CAGR of 4.5% during the forecast period, i.e., between 2026-2035.
The major players in the market are ALK-Abelló, Stallergenes Greer, Allergy Therapeutics, HAL Allergy, DBV Technologies, and others.
In terms of the allergy type segment, the allergic rhinitis segment is anticipated to garner the largest market share of 71.9% by 2035 and display lucrative growth opportunities during 2026-2035.
The market in North America is projected to hold the largest market share of 40.5% by the end of 2035.
